Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 5/20 | 0.34 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743128 | 0.91 | TDO2 (0.38) | CD44CYP3A4TSHRALDH1A1HPGD | |
| SCHEMBL3768021 | 0.89 | TDO2 (0.40) | CD44GAAPTGS2 | |
| SCHEMBL18989480 | 0.87 | HTR2C (0.38) | PDK2PDK4HTR2CUSP30IDO1 | |
| SCHEMBL22716824 | 0.86 | MAOA (0.35) | CD44 | |
| SCHEMBL28542565 | 0.85 | PARP1 (0.37) | CD44PDK2PDK4CYP3A4TSHR | |
| SCHEMBL30536161 | 0.85 | PARP1 (0.37) | CD44PDK2PDK4CYP3A4TSHR | |
| SCHEMBL29253795 | 0.82 | HTR1D (0.46) | CYP3A4SLC6A2SLC6A4SLC6A3RGS12 | |
| SCHEMBL22716846 | 0.80 | NOS3 (0.37) | CD44CYP3A4TSHRALDH1A1HPGD | |
| SCHEMBL744815 | 0.80 | ALOX15 (0.45) | CYP3A4TSHRALDH1A1ALOX15CASP1 | |
| SCHEMBL15271549 | 0.80 | PDE10A (0.35) | CD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4311577-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Ji Xing Pharmaceuticals Hong Kong Limited (HK) | 2024-01-31 | — | — | EP | disclosed |
| EP-3562487-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023166303-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-09-07 | — | — | WO | disclosed |
| EP-4208442-A1 | NOVEL COMPOUNDS | NRG Therapeutics LTD (GB) | 2023-07-12 | — | — | EP | disclosed |
| CN-116096705-A | Novel compounds | NRG治疗有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-114269383-A | Metalloenzyme inhibitor compounds | 菲斯生物制药公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20210322409-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2021-10-21 | — | — | US | disclosed |
| US-11040034-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| CN-110691598-A | Metalloenzyme inhibitor compounds | 赛列尼蒂治疗(百慕大)有限公司 | 2020-01-14 | — | — | CN | disclosed |
| EP-3562487-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Selenity Therapeutics (Bermuda), Ltd. (BM) | 2019-11-06 | — | — | EP | disclosed |
| US-20190008861-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2019-01-10 | — | — | US | disclosed |
| US-10085984-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-10-02 | — | — | US | disclosed |
| US-20180185362-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| WO-2018125800-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |
| WO-2017076194-A1 | COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST HCV, PREPARATION METHOD AND USE THEREOF | 江苏豪森药业集团有限公司 | 2017-05-11 | — | — | WO | disclosed |
| WO-2009100045-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185362-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | CD44 2269/4885PDK2 1026/4885PDK4 791/4885 |
| US-20210322409-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | CD44 2269/4885PDK2 1026/4885PDK4 791/4885 |
| US-11040034-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | CD44 2269/4885PDK2 1026/4885PDK4 791/4885 |
| US-20190008861-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | CD44 2269/4885PDK2 1026/4885PDK4 791/4885 |
| US-10085984-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | CD44 2269/4885PDK2 1026/4885PDK4 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.